budesonide/formoterol, 2x 200/6 microgram. 4 times daily

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease

Clinical Trial

Last updated: 2/9/2026

Developer

AZN

AstraZeneca PLC

Related Pipeline

Irritable Bowel Syndrome With Constipation (IBS-C)

Muscle Invasive Bladder Cancer

Asthma, Exercise-Induced

Affective Psychosis, Bipolar

Carcinoma, Non-Small-Cell Lung